Immunization Against Hepatitis A

Immunization against Hepatitis A provides effective protection for adults (over 15 years old) and children (1-15 years old, including 15 years old). With precise dosages in two specifications, completing the full two-dose vaccination course can induce long-lasting, even lifelong, protective antibodies, effectively blocking virus transmission. It is a core tool for building individual and community immunity barriers and a reliable choice for public health and personal health protection.

Choose AIM Action Biopharmaceutical Co., Ltd. to gain a vaccine supplier with whom you can have a long-term partnership and who possesses continuous innovation and research and development capabilities.

Why Is Hepatitis A Vaccination Needed?

Hepatitis A (HA) is a globally significant public health challenge caused by the hepatitis A virus (HAV), an acute gastrointestinal infectious disease. The virus primarily spreads through the fecal-oral route, transmitted via contaminated food or water, through direct or indirect contact with infected individuals.

Adults infected with HAV typically exhibit more severe clinical symptoms than children and may progress to acute liver failure. According to the 2019 Global Burden of Disease Collaborative Net work (GBD) database, approximately 159 million people worldwide contract acute HAV annually, resulting in 39,000 deaths and 2.3 million disabilities. In 2016, the World Health Organization (WHO) established the global target to "eliminate viral hepatitis as a public health threat by 2030."

Hepatitis A is prevalent worldwide, primarily as sporadic cases. The prevalence of HAV shows significant regional variations, commonly seen in low-and middle-income countries with poor sanitation and suboptimal hygiene practices. Based on the level of HAV prevalence, regions can be classified as highly, moderately, or mildly endemic. Approximately 1.5 million HAV cases are reported globally each year.

However, since most children under 6 years old infected with HAV show no symptoms, the estimated number of actual HAV infections worldwide exceeds 159 million annually. Globally, 66% of acute hepatitis A cases and 97% of hepatitis A-related deaths occur in low-and lower-middle-income countries. (Expert Recommendations on Hepatitis A Vaccination in Adults, China Journal of Viral Diseases, Vol. 13, No.6, November 2023)

Why Choose AIM Vaccine Products?

Immunization against hepatitis A refers to the process of acquiring specific immunity against the hepatitis A virus through the administration of a hepatitis A vaccine, which is the fundamental strategy for preventing and controlling hepatitis A.

The inactivated hepatitis A vaccine produced by AIM Action strictly adheres to China's immunization program strategies and vaccination schedules. It is prepared using human diploid cell culture and inactivation purification technology, containing no live virus and offering high safety. The vaccine antigens are carefully proportioned to efficiently stimulate the immune system to produce long-lasting antibodies.

Whether included in the primary immunization program for children or used as boost immunization for adults, especially high-risk populations, this product is a high-quality option with strict batch release certification. It is currently undergoing registration and marketing applications in multiple Southeast Asian countries, striving to contribute to the public health goal of "proactive prevention and staying away from hepatitis A."

The Hepatitis A vaccine by AIM Action provides tailored immunization programmes for different populations